Accelerate Diagnostics (AXDX) to Release Earnings on Monday

Accelerate Diagnostics (NASDAQ:AXDXGet Rating) will be posting its quarterly earnings results after the market closes on Monday, May 16th. Analysts expect Accelerate Diagnostics to post earnings of ($0.32) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Accelerate Diagnostics (NASDAQ:AXDXGet Rating) last released its quarterly earnings results on Tuesday, March 8th. The medical research company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.07. The business had revenue of $3.30 million during the quarter, compared to analysts’ expectations of $3.20 million. During the same period in the previous year, the business earned ($0.33) EPS. On average, analysts expect Accelerate Diagnostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:AXDX opened at $0.80 on Monday. The business’s 50-day moving average price is $1.47 and its two-hundred day moving average price is $3.44. Accelerate Diagnostics has a twelve month low of $0.72 and a twelve month high of $9.36. The stock has a market cap of $55.94 million, a P/E ratio of -0.64 and a beta of 1.90.

In related news, CFO Steven Reichling sold 29,915 shares of the firm’s stock in a transaction that occurred on Thursday, April 28th. The stock was sold at an average price of $0.98, for a total transaction of $29,316.70. Following the transaction, the chief financial officer now directly owns 62,493 shares in the company, valued at approximately $61,243.14. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Jack Phillips sold 83,708 shares of the firm’s stock in a transaction that occurred on Thursday, April 28th. The stock was sold at an average price of $0.98, for a total value of $82,033.84. Following the transaction, the chief executive officer now owns 208,073 shares in the company, valued at $203,911.54. The disclosure for this sale can be found here. Insiders have sold a total of 128,695 shares of company stock worth $126,121 over the last quarter. Corporate insiders own 42.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXDX. BNP Paribas Arbitrage SA increased its stake in shares of Accelerate Diagnostics by 415.6% during the third quarter. BNP Paribas Arbitrage SA now owns 6,213 shares of the medical research company’s stock valued at $36,000 after buying an additional 5,008 shares during the period. Citigroup Inc. raised its holdings in Accelerate Diagnostics by 101.3% in the 4th quarter. Citigroup Inc. now owns 8,814 shares of the medical research company’s stock worth $46,000 after purchasing an additional 4,436 shares in the last quarter. Squarepoint Ops LLC bought a new position in Accelerate Diagnostics in the 4th quarter worth $58,000. Two Sigma Investments LP bought a new position in Accelerate Diagnostics in the 3rd quarter worth $77,000. Finally, Invesco Ltd. raised its holdings in Accelerate Diagnostics by 25.5% in the 3rd quarter. Invesco Ltd. now owns 14,353 shares of the medical research company’s stock worth $85,000 after purchasing an additional 2,919 shares in the last quarter. Institutional investors and hedge funds own 65.50% of the company’s stock.

Several research firms have weighed in on AXDX. Zacks Investment Research cut Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, January 25th. StockNews.com began coverage on Accelerate Diagnostics in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Craig Hallum cut Accelerate Diagnostics from a “buy” rating to a “hold” rating and set a $5.00 price target on the stock. in a report on Wednesday, March 9th. Finally, William Blair reaffirmed an “outperform” rating on shares of Accelerate Diagnostics in a report on Wednesday, March 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Accelerate Diagnostics currently has a consensus rating of “Hold” and a consensus price target of $6.42.

About Accelerate Diagnostics (Get Rating)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Recommended Stories

Earnings History for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.